1 der development for the topical treatment of onychomycosis.

2 agnosis and treatment of dermatophytosis and onychomycosis.

3 ified in United States patients with toenail onychomycosis.

4 H(2)S donor is a promising new treatment for onychomycosis.

5 deliver terbinafine to the nail bed to treat onychomycosis.

6 tion for a more efficacious therapy to treat onychomycosis, a fungal infection of the toe and fingern

7 talidium dimidiatum is a mold known to cause onychomycosis and dermatomycosis; however, it is an extr

8  by dermatophytes such as athlete's foot and onychomycosis are distressingly common, life-threatening

9         All patients should be evaluated for onychomycosis because this may complicate psoriatic nail

10 ese infants and 1 health care worker who had onychomycosis had the same clone.

11 superficial infections such as keratitis and onychomycosis in immunocompetent humans; however, infect

12 AN2690), in development for the treatment of onychomycosis, inhibits yeast cytoplasmic leucyl-tRNA sy

13 with terbinafine for patients with suspected onychomycosis is more cost-effective than confirmatory t

14                                              Onychomycosis is the most common disease of the nail in

15 tion of TDT 067 for the topical treatment of onychomycosis is warranted.

16 cision analysis that compared the costs of 3 onychomycosis management algorithms based on recently pu

17     Primary outcomes included direct cost of onychomycosis testing and therapy and cost to avoid harm

18 ), which is currently in clinical trials for onychomycosis topical treatment.

19    Samples from 15,683 patients suspected of onychomycosis visiting the offices of dermatologists and

20 used antifungal to treat dermatophytosis and onychomycosis worldwide, is being increasingly reported.